ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2021
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text.
2 registry-linked trialsAbstract read
In one paragraph
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Sock Developed Wıth Wearable Technology for Patıents Undergoıng Transurethral Resectıon Surgery on the Development of Hypothermıa and Venous Thromboembolısm
A Feasibility Randomized Controlled Trial Evaluating Early vs Late Stent Removal Following Radical Cystectomy and Ileal Conduit Formation for Bladder Cancer
Who cites it
23 citing papers in PubMed.
- A minor high-grade component in non-invasive papillary urothelial carcinoma is not associated with a more indolent behaviour.Histopathology · 2026Article
- Beyond the Rotisserie: Dispelling the Myths of Intravesical Therapy and Pioneering a Precision Future for Bladder Cancer.Urology research & practice · 2026Article
- Advances in the management of localized bladder cancers.Nature reviews. Clinical oncology · 2026Review
- Contemporary Role for Blue Light Cystoscopy Across the Bladder Cancer Disease Spectrum.Current urology reports · 2026Review
- Sequential Intravesical Gemcitabine and Docetaxel for Non-Muscle Invasive Bladder Cancer: A Narrative Review Across Risk Groups.Research and reports in urology · 2026Review
- Differential effects of BCG-Russia and BCG-TICE on trained immunity: Potential implications for bladder cancer immunotherapy.PloS one · 2026Article
- A population-based analysis of patterns of care in patients with de novo muscle-invasive bladder cancer from Alberta, Canada.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Guideline adherence in treating non-muscle-invasive bladder cancer: Discipline can save lives.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- A population-based analysis of patterns of care in patients with high-risk non-muscle-invasive bladder cancer from Alberta, Canada.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression risk.BJU international · 2025Article
- Assessing the methodologic heterogeneity of Canadian Urological Association guidelines Adoption of the GRADE approach (2018-2023).Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Pharmacological Inhibition of Endogenous Hydrogen Sulfide Production Slows Bladder Cancer Progression in an Intravesical Murine Model.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
- Is switching intravesical chemotherapeutic agents beneficial in short-term recurrent high-risk non-muscle-invasive bladder tumors? A 5-year retrospective study.BMC urology · 2024Article
- A Real-World Retrospective Analysis of the Management of Advanced Urothelial Carcinoma in Canada.Current oncology (Toronto, Ont.) · 2024Article
- Review
- Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer.Journal of health economics and outcomes research · 2024Article
- Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database.Frontiers in immunology · 2024Observational
- Existing trends and applications of artificial intelligence in urothelial cancer A scoping review.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- Adherence to guidelines in the follow-up of non-muscle-invasive bladder cancer among urology trainers and trainees in Jordan: a cross-sectional study.Annals of medicine and surgery (2012) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Bimal BhindiSection of Urology, Department of Surgery, University of Calgary, Calgary, AB, Canada.
Ronald KoolDivision of Urology, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada.
Girish S KulkarniDivision of Urology, Department of Surgery, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
D Robert SiemensDepartment of Urology, Queen's University, Kingston, ON, Canada.
Armen G AprikianDivision of Urology, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada.
Rodney H BreauDivision of Urology, University of Ottawa, Clinical Epidemiology, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Fadi BrimoDepartment of Pathology, McGill University Health Centre, Montreal, QC, Canada.
Adrian FaireyDivision of Urology, University of Alberta, Edmonton, AB, Canada.
Christopher FrenchDivision of Urology, Department of Surgery, Memorial University of Newfoundland, St. John's, NL, Canada.
Nawar HannaDepartment of Urology, Université de Montréal, Montreal, QC, Canada.
Jonathan I IzawaDepartment of Surgery, Division of Urology, Western University, London, ON, Canada.
Louis LacombeDepartment of Surgery, Faculty of Medicine, Université Laval, Laval, QC, Canada.
Victor McPhersonDivision of Urology, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada.
Ricardo A RendonDepartment of Urology, Dalhousie University, Halifax, NS, Canada.
Bobby ShayeganDivision of Urology, McMaster University, Hamilton, ON, Canada.
Alan I SoDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Alexandre R ZlottaDivision of Urology, Department of Surgery, Sinai Health System and Department of Surgical Oncology, University Health Network, Toronto, ON, Canada.
Peter C BlackDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Wassim KassoufDivision of Urology, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT05887518ClinicalTrials.gov
NCT06595446ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.